BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sun BS, Dong QZ, Ye QH, Sun HJ, Jia HL, Zhu XQ, Liu DY, Chen J, Xue Q, Zhou HJ. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology. 2008;48:1834-1842. [PMID: 18972404 DOI: 10.1002/hep.22531] [Cited by in Crossref: 113] [Cited by in F6Publishing: 112] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Phillips RJ, Helbig KJ, Hoek KHVD, Seth D, Beard MR. Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner. World J Gastroenterol 2012; 18(26): 3389-3399 [PMID: 22807608 DOI: 10.3748/wjg.v18.i26.3389] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
2 Qi J, Li T, Bian H, Li F, Ju Y, Gao S, Su J, Ren W, Qin C. SNAI1 promotes the development of HCC through the enhancement of proliferation and inhibition of apoptosis. FEBS Open Bio 2016;6:326-37. [PMID: 27239445 DOI: 10.1002/2211-5463.12043] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
3 Zhu W, Guo L, Zhang B, Lou L, Lin Z, Zhu X, Ren N, Dong Q, Ye Q, Qin L. Combination of osteopontin with peritumoral infiltrating macrophages is associated with poor prognosis of early-stage hepatocellular carcinoma after curative resection. Ann Surg Oncol. 2014;21:1304-1313. [PMID: 24366422 DOI: 10.1245/s10434-013-3445-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
4 Pouya FD, Rasmi Y, Gazouli M, Zografos E, Nemati M. MicroRNAs as therapeutic targets in breast cancer metastasis. Drug Deliv Transl Res 2021. [PMID: 33987801 DOI: 10.1007/s13346-021-00999-2] [Reference Citation Analysis]
5 Noguchi S, Kumazaki M, Mori T, Baba K, Okuda M, Mizuno T, Akao Y. Analysis of microRNA-203 function in CREB/MITF/RAB27a pathway: comparison between canine and human melanoma cells. Vet Comp Oncol 2016;14:384-94. [PMID: 25280339 DOI: 10.1111/vco.12118] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
6 Lin Q, Li J, Zhu D, Niu Z, Pan X, Xu P, Ji M, Wei Y, Xu J. Aberrant Scinderin Expression Correlates With Liver Metastasis and Poor Prognosis in Colorectal Cancer. Front Pharmacol 2019;10:1183. [PMID: 31736743 DOI: 10.3389/fphar.2019.01183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Jia Q, Xue T, Zhang Q, Cheng W, Zhang C, Ma J, Bu Y, Yu S, Liu Q. CCN3 is a therapeutic target relating enhanced stemness and coagulation in hepatocellular carcinoma. Sci Rep 2017;7:13846. [PMID: 29061995 DOI: 10.1038/s41598-017-14087-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
8 Ohno K, Nishimori H, Yasoshima T, Kamiguchi K, Hata F, Fukui R, Okuya K, Kimura Y, Denno R, Kon S. Inhibition of osteopontin reduces liver metastasis of human pancreatic cancer xenografts injected into the spleen in a mouse model. Surg Today. 2010;40:347-356. [PMID: 20339989 DOI: 10.1007/s00595-009-4082-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
9 Noguchi S, Yasui Y, Iwasaki J, Kumazaki M, Yamada N, Naito S, Akao Y. Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer Lett. 2013;328:353-361. [PMID: 23104321 DOI: 10.1016/j.canlet.2012.10.017] [Cited by in Crossref: 92] [Cited by in F6Publishing: 92] [Article Influence: 9.2] [Reference Citation Analysis]
10 Noguchi S, Mori T, Nakagawa T, Itamoto K, Haraguchi T, Mizuno T. DNA methylation contributes toward silencing of antioncogenic microRNA-203 in human and canine melanoma cells. Melanoma Res 2015;25:390-8. [PMID: 26225581 DOI: 10.1097/CMR.0000000000000183] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
11 Noguchi S, Iwasaki J, Kumazaki M, Mori T, Maruo K, Sakai H, Yamada N, Shimada K, Naoe T, Kitade Y, Akao Y. Chemically modified synthetic microRNA-205 inhibits the growth of melanoma cells in vitro and in vivo. Mol Ther 2013;21:1204-11. [PMID: 23629002 DOI: 10.1038/mt.2013.70] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
12 Shevde LA, Das S, Clark DW, Samant RS. Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med. 2010;10:71-81. [PMID: 20205680 DOI: 10.2174/156652410791065381] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 7.9] [Reference Citation Analysis]
13 Ang C, O'Reilly EM, Abou-Alfa GK. MicroRNA, hypoxic stress and hepatocellular carcinoma: future directions. J Gastroenterol Hepatol 2011;26:1586-8. [PMID: 22011295 DOI: 10.1111/j.1440-1746.2011.06903.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
14 Wu JC, Sun BS, Ren N, Ye QH, Qin LX. Genomic aberrations in hepatocellular carcinoma related to osteopontin expression detected by array-CGH. J Cancer Res Clin Oncol. 2010;136:595-601. [PMID: 19834740 DOI: 10.1007/s00432-009-0695-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zhang CH, Xu GL, Jia WD, Ge YS, Li JS, Ma JL, Ren WH. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer 2012;130:2685-92. [PMID: 21780114 DOI: 10.1002/ijc.26301] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
16 Sun T, Li P, Sun D, Bu Q, Li G. Prognostic value of osteopontin in patients with hepatocellular carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e12954. [PMID: 30412113 DOI: 10.1097/MD.0000000000012954] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
17 Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012;55:483-90. [PMID: 21953299 DOI: 10.1002/hep.24703] [Cited by in Crossref: 185] [Cited by in F6Publishing: 184] [Article Influence: 16.8] [Reference Citation Analysis]
18 Lee YJ, Jang BK. Can combination of osteopontin and peritumor-infiltrating macrophages be a prognostic marker of early-stage hepatocellular carcinoma? Hepatobiliary Surg Nutr 2014;3:57-9. [PMID: 24812596 DOI: 10.3978/j.issn.2304-3881.2014.02.11] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Joshi P, Middleton J, Jeon YJ, Garofalo M. MicroRNAs in lung cancer. World J Methodol 2014; 4(2): 59-72 [PMID: 25332906 DOI: 10.5662/wjm.v4.i2.59] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
20 Liu Z, Chang H, Hou Y, Wang Y, Zhou Z, Wang M, Huang Z, Yu B. Lentivirus‑mediated microRNA‑26a overexpression in bone mesenchymal stem cells facilitates bone regeneration in bone defects of calvaria in mice. Mol Med Rep 2018;18:5317-26. [PMID: 30365148 DOI: 10.3892/mmr.2018.9596] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
21 Sangar V, Funk CC, Kusebauch U, Campbell DS, Moritz RL, Price ND. Quantitative proteomic analysis reveals effects of epidermal growth factor receptor (EGFR) on invasion-promoting proteins secreted by glioblastoma cells. Mol Cell Proteomics 2014;13:2618-31. [PMID: 24997998 DOI: 10.1074/mcp.M114.040428] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
22 Ivacik D, Ely A, Ferry N, Arbuthnot P. Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses. Gene Ther. 2015;22:163-171. [PMID: 25338920 DOI: 10.1038/gt.2014.94] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
23 Zhao H, Chen Q, Alam A, Cui J, Suen KC, Soo AP, Eguchi S, Gu J, Ma D. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis 2018;9:356. [PMID: 29500465 DOI: 10.1038/s41419-018-0391-6] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 23.5] [Reference Citation Analysis]
24 Zhu Y, Gao XM, Yang J, Xu D, Zhang Y, Lu M, Zhang Z, Sheng YY, Li JH, Yu XX, Zheng Y, Dong QZ, Qin LX. C-C chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma. Cancer Sci 2018;109:710-23. [PMID: 29285854 DOI: 10.1111/cas.13487] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
25 Zhang G, Wang Q, Xu R. Therapeutics Based on microRNA: A New Approach for Liver Cancer. Curr Genomics 2010;11:311-25. [PMID: 21286309 DOI: 10.2174/138920210791616671] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
26 George J, Patel T. Noncoding RNA as therapeutic targets for hepatocellular carcinoma. Semin Liver Dis. 2015;35:63-74. [PMID: 25632936 DOI: 10.1055/s-0034-1397350] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
27 Li Y, Zhang X, Yang X, Liu J, Li L, Ma W, Chen M. Differential effects of ginkgol C17:1 on cisplatin-induced cytotoxicity: Protecting human normal L02 hepatocytes versus sensitizing human hepatoma HepG2 cells. Oncol Lett 2019;17:3181-90. [PMID: 30867748 DOI: 10.3892/ol.2019.9974] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Noguchi S, Mori T, Otsuka Y, Yamada N, Yasui Y, Iwasaki J, Kumazaki M, Maruo K, Akao Y. Anti-oncogenic microRNA-203 induces senescence by targeting E2F3 protein in human melanoma cells. J Biol Chem 2012;287:11769-77. [PMID: 22354972 DOI: 10.1074/jbc.M111.325027] [Cited by in Crossref: 83] [Cited by in F6Publishing: 44] [Article Influence: 8.3] [Reference Citation Analysis]
29 Sieghart W, Wang X, Schmid K, Pinter M, König F, Bodingbauer M, Wrba F, Rasoul-Rockenschaub S, Peck-Radosavljevic M. Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. J Hepatol. 2011;54:89-97. [PMID: 20970216 DOI: 10.1016/j.jhep.2010.06.030] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
30 Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, Li CW, Lim SO, Sheng YY, Zhang Y, Li JH, Luo Q, Zheng Y, Zhao Y, Lu L, Jia HL, Hung MC, Dong QZ, Qin LX. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut. 2019;68:1653-1666. [PMID: 30902885 DOI: 10.1136/gutjnl-2019-318419] [Cited by in Crossref: 83] [Cited by in F6Publishing: 89] [Article Influence: 27.7] [Reference Citation Analysis]
31 Cervello M, Augello G, Cusimano A, Emma MR, Balasus D, Azzolina A, Mccubrey JA, Montalto G. Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma. Advances in Biological Regulation 2017;65:59-76. [DOI: 10.1016/j.jbior.2017.06.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
32 Sun JY, Xu JM, Yan M, Ye F. Advances in understanding relationship between osteopontin and metastasis and recurrence of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2013; 21(16): 1498-1504 [DOI: 10.11569/wcjd.v21.i16.1498] [Reference Citation Analysis]
33 Chen RX, Xia YH, Cui JF, Xue TC, Ye SL. Osteopontin, a single marker for predicting the prognosis of patients with tumor-node-metastasis stage I hepatocellular carcinoma after surgical resection. J Gastroenterol Hepatol. 2010;25:1435-1442. [PMID: 20659235 DOI: 10.1111/j.1440-1746.2010.06277.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
34 Dong Q, Zhu X, Dai C, Zhang X, Gao X, Wei J, Sheng Y, Zheng Y, Yu J, Xie L, Qin Y, Qiao P, Zhou C, Yu X, Jia H, Ren N, Zhou H, Ye Q, Qin L. Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin. Oncotarget 2016;7:12997-3012. [PMID: 26824421 DOI: 10.18632/oncotarget.7016] [Cited by in Crossref: 36] [Cited by in F6Publishing: 45] [Article Influence: 7.2] [Reference Citation Analysis]
35 Wong CC, Wong CM, Tung EK, Man K, Ng IO. Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology. 2009;49:1583-1594. [PMID: 19205033 DOI: 10.1002/hep.22836] [Cited by in Crossref: 92] [Cited by in F6Publishing: 95] [Article Influence: 7.1] [Reference Citation Analysis]
36 Cheng J, Wang W, Sun C, Li M, Wang B, Lv Y. Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma. J Clin Gastroenterol 2014;48:806-14. [PMID: 24247813 DOI: 10.1097/MCG.0000000000000018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
37 Musso G, Paschetta E, Gambino R, Cassader M, Molinaro F. Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. Trends Mol Med. 2013;19:522-535. [PMID: 23816817 DOI: 10.1016/j.molmed.2013.05.006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
38 Weismann D, Briese J, Niemann J, Grüneberger M, Adam P, Hahner S, Johanssen S, Liu W, Ezzat S, Saeger W, Bamberger AM, Fassnacht M, Schulte HM, Asa SL, Allolio B, Bamberger CM. Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma. J Pathol 2009;218:232-40. [PMID: 19326399 DOI: 10.1002/path.2528] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
39 Wang H, Chen L. Tumor microenviroment and hepatocellular carcinoma metastasis. J Gastroenterol Hepatol 2013;28 Suppl 1:43-8. [PMID: 23855295 DOI: 10.1111/jgh.12091] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 6.5] [Reference Citation Analysis]
40 Shen W, Wang CY, Wang XH, Fu ZX. Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo. J Exp Clin Cancer Res 2009;28:81. [PMID: 19527508 DOI: 10.1186/1756-9966-28-81] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
41 Ferrín G, Aguilar-Melero P, Rodríguez-Perálvarez M, Montero-Álvarez JL, de la Mata M. Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility. Hepat Med 2015;7:1-10. [PMID: 25926760 DOI: 10.2147/HMER.S50161] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
42 Liu G, Fan X, Tang M, Chen R, Wang H, Jia R, Zhou X, Jing W, Wang H, Yang Y. Osteopontin induces autophagy to promote chemo-resistance in human hepatocellular carcinoma cells. Cancer Lett. 2016;383:171-182. [PMID: 27702661 DOI: 10.1016/j.canlet.2016.09.033] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
43 Breig O, Yates M, Neaud V, Couchy G, Grigoletto A, Lucchesi C, Prox J, Zucman-Rossi J, Becker-Pauly C, Rosenbaum J. Metalloproteinase meprin α regulates migration and invasion of human hepatocarcinoma cells and is a mediator of the oncoprotein Reptin. Oncotarget 2017;8:7839-51. [PMID: 27999200 DOI: 10.18632/oncotarget.13975] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
44 Li H, Ren Z, Kang X, Zhang L, Li X, Wang Y, Xue T, Shen Y, Liu Y. Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells. BMC Cancer 2009;9:366. [PMID: 19835603 DOI: 10.1186/1471-2407-9-366] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 3.4] [Reference Citation Analysis]
45 Qu L, Deng B, Zeng Y, Cao Z. Decreased expression of the Nkx2.8 gene correlates with tumor progression and a poor prognosis in HCC cancer. Cancer Cell Int 2014;14:28. [PMID: 24678995 DOI: 10.1186/1475-2867-14-28] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
46 Henry A, Nokin MJ, Leroi N, Lallemand F, Lambert J, Goffart N, Roncarati P, Bianchi E, Peixoto P, Blomme A, Turtoi A, Peulen O, Habraken Y, Scholtes F, Martinive P, Delvenne P, Rogister B, Castronovo V, Bellahcène A. New role of osteopontin in DNA repair and impact on human glioblastoma radiosensitivity. Oncotarget 2016;7:63708-21. [PMID: 27563812 DOI: 10.18632/oncotarget.11483] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
47 Kotowska-Zimmer A, Pewinska M, Olejniczak M. Artificial miRNAs as therapeutic tools: Challenges and opportunities. Wiley Interdiscip Rev RNA 2021;12:e1640. [PMID: 33386705 DOI: 10.1002/wrna.1640] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX, Wang XW. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010;70:10202-10212. [PMID: 21159642 DOI: 10.1158/0008-5472.can-10-2607] [Cited by in Crossref: 478] [Cited by in F6Publishing: 391] [Article Influence: 43.5] [Reference Citation Analysis]
49 Chen RX, Xia YH, Xue TC, Ye SL. Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression. Mol Biol Rep 2011;38:3671-7. [PMID: 21104439 DOI: 10.1007/s11033-010-0481-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
50 Liu FJ, Wen T, Liu L. MicroRNAs as a novel cellular senescence regulator. Ageing Res Rev 2012;11:41-50. [PMID: 21689787 DOI: 10.1016/j.arr.2011.06.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
51 Wen Y, Jeong S, Xia Q, Kong X. Role of Osteopontin in Liver Diseases. Int J Biol Sci 2016;12:1121-8. [PMID: 27570486 DOI: 10.7150/ijbs.16445] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
52 Yang G, Zhang S, Zhang Y, Zhou Q, Peng S, Zhang T, Yang C, Zhu Z, Zhang F. The inhibitory effects of extracellular ATP on the growth of nasopharyngeal carcinoma cells via P2Y2 receptor and osteopontin. J Exp Clin Cancer Res 2014;33:53. [PMID: 24961145 DOI: 10.1186/1756-9966-33-53] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
53 Noguchi S, Kumazaki M, Yasui Y, Mori T, Yamada N, Akao Y. MicroRNA-203 regulates melanosome transport and tyrosinase expression in melanoma cells by targeting kinesin superfamily protein 5b. J Invest Dermatol 2014;134:461-9. [PMID: 23884313 DOI: 10.1038/jid.2013.310] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 5.0] [Reference Citation Analysis]
54 Zhang R, Lin XH, Ma M, Chen J, Chen J, Gao DM, Cui JF, Chen RX. Periostin involved in the activated hepatic stellate cells-induced progression of residual hepatocellular carcinoma after sublethal heat treatment: its role and potential for therapeutic inhibition. J Transl Med 2018;16:302. [PMID: 30400797 DOI: 10.1186/s12967-018-1676-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
55 Yu X, Zheng Y, Zhu X, Gao X, Wang C, Sheng Y, Cheng W, Qin L, Ren N, Jia H, Dong Q. Osteopontin promotes hepatocellular carcinoma progression via the PI3K/AKT/Twist signaling pathway. Oncol Lett 2018;16:5299-308. [PMID: 30250599 DOI: 10.3892/ol.2018.9281] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
56 Nabih MI, Aref WM, Fathy MM. Significance of plasma osteopontin in diagnosis of hepatitis C virus-related hepatocellular carcinoma. Arab J Gastroenterol. 2014;15:103-107. [PMID: 25249230 DOI: 10.1016/j.ajg.2014.08.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
57 Diao H, Liu X, Wu Z, Kang L, Cui G, Morimoto J, Denhardt DT, Rittling S, Iwakura Y, Uede T, Li L. Osteopontin regulates interleukin-17 production in hepatitis. Cytokine 2012;60:129-37. [PMID: 22818182 DOI: 10.1016/j.cyto.2012.06.287] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
58 Potikha T, Pappo O, Mizrahi L, Olam D, Maller SM, Rabinovich GA, Galun E, Goldenberg DS. Lack of galectin‐1 exacerbates chronic hepatitis, liver fibrosis, and carcinogenesis in murine hepatocellular carcinoma model. FASEB j 2019;33:7995-8007. [DOI: 10.1096/fj.201900017r] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
59 Long J, Chen P, Lin J, Bai Y, Yang X, Bian J, Lin Y, Wang D, Yang X, Zheng Y, Sang X, Zhao H. DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. Theranostics. 2019;9:7251-7267. [PMID: 31695766 DOI: 10.7150/thno.31155] [Cited by in Crossref: 17] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
60 Wong CC, Kai AK, Ng IO. The impact of hypoxia in hepatocellular carcinoma metastasis. Front Med 2014;8:33-41. [PMID: 24234682 DOI: 10.1007/s11684-013-0301-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 5.3] [Reference Citation Analysis]
61 Liao W, Liu W, Yuan Q, Liu X, Ou Y, He S, Yuan S, Qin L, Chen Q, Nong K, Mei M, Huang J. Silencing of DLGAP5 by siRNA significantly inhibits the proliferation and invasion of hepatocellular carcinoma cells. PLoS One 2013;8:e80789. [PMID: 24324629 DOI: 10.1371/journal.pone.0080789] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
62 Calloni R, Bonatto D. Scaffolds for Artificial miRNA Expression in Animal Cells. Hum Gene Ther Methods 2015;26:162-74. [PMID: 26406928 DOI: 10.1089/hgtb.2015.043] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
63 Song Z, Chen W, Athavale D, Ge X, Desert R, Das S, Han H, Nieto N. Osteopontin Takes Center Stage in Chronic Liver Disease. Hepatology 2021;73:1594-608. [PMID: 32986864 DOI: 10.1002/hep.31582] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
64 Sulpice L, Rayar M, Desille M, Turlin B, Fautrel A, Boucher E, Llamas-Gutierrez F, Meunier B, Boudjema K, Clément B. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology. 2013;58:1992-2000. [PMID: 23775819 DOI: 10.1002/hep.26577] [Cited by in Crossref: 77] [Cited by in F6Publishing: 125] [Article Influence: 8.6] [Reference Citation Analysis]
65 Qi W, Liang W, Jiang H, Miuyee Waye M. The function of miRNA in hepatic cancer stem cell. Biomed Res Int 2013;2013:358902. [PMID: 24383051 DOI: 10.1155/2013/358902] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
66 Qin L. Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies. Front Med. 2014;8:24-32. [PMID: 24464486 DOI: 10.1007/s11684-014-0312-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
67 Liu XY, Tang QS, Chen HC, Jiang XL, Fang H. Lentiviral miR30-based RNA interference against heparanase suppresses melanoma metastasis with lower liver and lung toxicity. Int J Biol Sci 2013;9:564-77. [PMID: 23847439 DOI: 10.7150/ijbs.5425] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
68 Chiodoni C, Colombo MP, Sangaletti S. Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer Metastasis Rev 2010;29:295-307. [PMID: 20386958 DOI: 10.1007/s10555-010-9221-8] [Cited by in Crossref: 155] [Cited by in F6Publishing: 146] [Article Influence: 12.9] [Reference Citation Analysis]
69 Lin Y, Huang G, Jin H, Jian Z. Circular RNA Gprc5a Promotes HCC Progression by Activating YAP1/TEAD1 Signalling Pathway by Sponging miR-1283. Onco Targets Ther 2020;13:4509-21. [PMID: 32547082 DOI: 10.2147/OTT.S240261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 Chen Y, Qian B, Sun X, Kang Z, Huang Z, Ding Z, Dong L, Chen J, Zhang J, Zang Y. Sox9/INHBB axis-mediated crosstalk between the hepatoma and hepatic stellate cells promotes the metastasis of hepatocellular carcinoma. Cancer Lett 2021;499:243-54. [PMID: 33246092 DOI: 10.1016/j.canlet.2020.11.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
71 Wei R, Wong JPC, Kwok HF. Osteopontin -- a promising biomarker for cancer therapy. J Cancer 2017;8:2173-83. [PMID: 28819419 DOI: 10.7150/jca.20480] [Cited by in Crossref: 62] [Cited by in F6Publishing: 69] [Article Influence: 12.4] [Reference Citation Analysis]
72 Liao X, Bu Y, Jiang S, Chang F, Jia F, Xiao X, Song G, Zhang M, Ning P, Jia Q. CCN2-MAPK-Id-1 loop feedback amplification is involved in maintaining stemness in oxaliplatin-resistant hepatocellular carcinoma. Hepatol Int 2019;13:440-53. [PMID: 31250351 DOI: 10.1007/s12072-019-09960-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
73 Cao DX, Li ZJ, Jiang XO, Lum YL, Khin E, Lee NP, Wu GH, Luk JM. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol 2012; 18(30): 3923-3930 [PMID: 22912540 DOI: 10.3748/wjg.v18.i30.3923] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 54] [Article Influence: 5.4] [Reference Citation Analysis]
74 Hamaoka K, Nagoshi S, Sugawara K, Naiki K, Uchida Y, Inao M, Nakayama N, Fujiwara K, Mochida S. SNPs in the promoter region of the osteopontin gene as a possible host factor for sex difference in hepatocellular carcinoma development in patients with HCV. Hepatol Int 2013;7:683-92. [PMID: 26201802 DOI: 10.1007/s12072-012-9404-1] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
75 Patouraux S, Bonnafous S, Voican CS, Anty R, Saint-Paul MC, Rosenthal-Allieri MA, Agostini H, Njike M, Barri-Ova N, Naveau S, Le Marchand-Brustel Y, Veillon P, Calès P, Perlemuter G, Tran A, Gual P. The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease. PLoS One 2012;7:e35612. [PMID: 22530059 DOI: 10.1371/journal.pone.0035612] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 5.8] [Reference Citation Analysis]
76 Liu YP, Berkhout B. miRNA cassettes in viral vectors: problems and solutions. Biochim Biophys Acta 2011;1809:732-45. [PMID: 21679781 DOI: 10.1016/j.bbagrm.2011.05.014] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 5.2] [Reference Citation Analysis]
77 Liao W, Liu W, Liu X, Yuan Q, Ou Y, Qi Y, Huang W, Wang Y, Huang J. Upregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma. Oncotarget 2015;6:24132-47. [PMID: 26125229 DOI: 10.18632/oncotarget.4432] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
78 Tian Y, Guo B, Jia H, Ji K, Sun Y, Li Y, Zhao T, Gao L, Meng Y, Kalvakolanu DV, Kopecko DJ, Zhao X, Zhang L, Xu D. Targeted therapy via oral administration of attenuated Salmonella expression plasmid-vectored Stat3-shRNA cures orthotopically transplanted mouse HCC. Cancer Gene Ther 2012;19:393-401. [PMID: 22555509 DOI: 10.1038/cgt.2012.12] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
79 Huang H, Zhang XF, Zhou HJ, Xue YH, Dong QZ, Ye QH, Qin LX. Expression and prognostic significance of osteopontin and caspase-3 in hepatocellular carcinoma patients after curative resection. Cancer Sci. 2010;101:1314-1319. [PMID: 20345480 DOI: 10.1111/j.1349-7006.2010.01524.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
80 Bhattacharya SD, Mi Z, Kim VM, Guo H, Talbot LJ, Kuo PC. Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model. Ann Surg. 2012;255:319-325. [PMID: 22241292 DOI: 10.1097/SLA.0b013e31823e3a1c] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
81 Herrera-Carrillo E, Liu YP, Berkhout B. Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors. Hum Gene Ther Methods 2017;28:177-90. [PMID: 28712309 DOI: 10.1089/hgtb.2017.036] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
82 Beudeker BJB, Boonstra A. Circulating biomarkers for early detection of hepatocellular carcinoma. Therap Adv Gastroenterol 2020;13:1756284820931734. [PMID: 32647536 DOI: 10.1177/1756284820931734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
83 Finnegan EF, Pasquinelli AE. MicroRNA biogenesis: regulating the regulators. Crit Rev Biochem Mol Biol 2013;48:51-68. [PMID: 23163351 DOI: 10.3109/10409238.2012.738643] [Cited by in Crossref: 176] [Cited by in F6Publishing: 166] [Article Influence: 17.6] [Reference Citation Analysis]
84 Tao ZH, Wan JL, Zeng LY, Xie L, Sun HC, Qin LX, Wang L, Zhou J, Ren ZG, Li YX. miR-612 suppresses the invasive-metastatic cascade in hepatocellular carcinoma. J Exp Med. 2013;210:789-803. [PMID: 23478189 DOI: 10.1084/jem.20120153] [Cited by in Crossref: 83] [Cited by in F6Publishing: 86] [Article Influence: 9.2] [Reference Citation Analysis]
85 Qin LX. Inflammatory immune responses in tumor microenvironment and metastasis of hepatocellular carcinoma. Cancer Microenviron. 2012;5:203-209. [PMID: 22678823 DOI: 10.1007/s12307-012-0111-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
86 Zheng W, Li R, Pan H, He D, Xu R, Guo TB, Guo Y, Zhang JZ. Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1β through the NF-κB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum 2009;60:1957-65. [DOI: 10.1002/art.24625] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 4.2] [Reference Citation Analysis]
87 Lee SH, Park JW, Woo SH, Go DM, Kwon HJ, Jang JJ, Kim DY. Suppression of osteopontin inhibits chemically induced hepatic carcinogenesis by induction of apoptosis in mice. Oncotarget 2016;7:87219-31. [PMID: 27888617 DOI: 10.18632/oncotarget.13529] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
88 Peng XC, Wang M, Chen XX, Liu J, Xiao GH, Liao HL. Plasmid-encoding vasostatin inhibited the growth and metastasis of human hepatocellular carcinoma cells. Mol Cell Biochem 2014;395:265-72. [PMID: 24997628 DOI: 10.1007/s11010-014-2135-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
89 Chen H, Mei Q, Jia S, Koh K, Wang K, Liu X. High specific detection of osteopontin using a three-dimensional copolymer layer support based on electrochemical impedance spectroscopy. Analyst 2014;139:4476-81. [PMID: 24992665 DOI: 10.1039/c4an00576g] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
90 Lu C, Fang S, Weng Q, Lv X, Meng M, Zhu J, Zheng L, Hu Y, Gao Y, Wu X, Mao J, Tang B, Zhao Z, Huang L, Ji J. Integrated analysis reveals critical glycolytic regulators in hepatocellular carcinoma. Cell Commun Signal 2020;18:97. [PMID: 32576292 DOI: 10.1186/s12964-020-00539-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
91 Ruiz de Galarreta M, Lujambio A. Hepatocellular carcinoma: killing one bird with two stones. Gut 2019;68:1543-4. [DOI: 10.1136/gutjnl-2019-318649] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Wang G, Chen S, Zhao C, Li X, Zhao W, Yang J, Chang C, Xu C. Comparative analysis of gene expression profiles of OPN signalling pathway in four kinds of liver diseases. J Genet 2016;95:741-50. [DOI: 10.1007/s12041-016-0673-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
93 Zhou C, Zhou HJ, Zhang XF, Lou LL, Ye QH, Zheng Y, Wang J, Zhu HT, Dong QZ, Jia HL, Zhu WW, Guo L, Zhao Y, Gao DM, Qin LX. Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma. Ann Surg Oncol 2013;20:929-37. [PMID: 23203407 DOI: 10.1245/s10434-012-2749-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
94 Dong QZ, Zhang XF, Zhao Y, Jia HL, Zhou HJ, Dai C, Sun HJ, Qin Y, Zhang WD, Ren N. Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma. Hepatology. 2013;57:1024-1034. [PMID: 23079960 DOI: 10.1002/hep.26103] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
95 Leung DT, Lim PL, Cheung TH, Wong RR, Yim SF, Ng MH, Tam FC, Chung TK, Wong YF. Osteopontin Fragments with Intact Thrombin-Sensitive Site Circulate in Cervical Cancer Patients. PLoS One 2016;11:e0160412. [PMID: 27494141 DOI: 10.1371/journal.pone.0160412] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
96 Liu X, Fang H, Chen H, Jiang X, Fang D, Wang Y, Zhu D. An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation. PLoS One. 2012;7:e38659. [PMID: 22719918 DOI: 10.1371/journal.pone.0038659] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
97 Likui W, Hong W, Shuwen Z. Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer. J Gastrointest Surg 2010;14:74-81. [PMID: 19763701 DOI: 10.1007/s11605-009-1035-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
98 Gao X, Sheng Y, Yang J, Wang C, Zhang R, Zhu Y, Zhang Z, Zhang K, Yan S, Sun H, Wei J, Wang X, Yu X, Zhang Y, Luo Q, Zheng Y, Qiao P, Zhao Y, Dong Q, Qin L. Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma. J Exp Clin Cancer Res 2018;37:179. [PMID: 30064482 DOI: 10.1186/s13046-018-0832-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
99 Li Y, Liu H, Zhao Y, Yue D, Chen C, Li C, Zhang Z, Wang C. Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC). Thorac Cancer 2021;12:2698-709. [PMID: 34423566 DOI: 10.1111/1759-7714.14108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Li G, Luna C, Qiu J, Epstein DL, Gonzalez P. Alterations in microRNA expression in stress-induced cellular senescence. Mech Ageing Dev 2009;130:731-41. [PMID: 19782699 DOI: 10.1016/j.mad.2009.09.002] [Cited by in Crossref: 134] [Cited by in F6Publishing: 137] [Article Influence: 11.2] [Reference Citation Analysis]
101 Tokuda K, Morine Y, Miyazaki K, Yamada S, Saito Y, Nishi M, Tokunaga T, Ikemoto T, Imura S, Shimada M. The interaction between cancer associated fibroblasts and tumor associated macrophages via the osteopontin pathway in the tumor microenvironment of hepatocellular carcinoma. Oncotarget 2021;12:333-43. [PMID: 33659044 DOI: 10.18632/oncotarget.27881] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
102 Lai S, Wang G, Cao X, Luo X, Wang G, Xia X, Hu J, Wang J. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors. Oncotarget 2016;7:1367-79. [PMID: 26587973 DOI: 10.18632/oncotarget.6011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
103 Mirzaei A, Mohammadi S, Ghaffari SH, Yaghmaie M, Vaezi M, Alimoghaddam K, Ghavamzadeh A. Osteopontin b and c Splice isoforms in Leukemias and Solid Tumors: Angiogenesis Alongside Chemoresistance. Asian Pac J Cancer Prev 2018;19:615-23. [PMID: 29580029 DOI: 10.22034/APJCP.2018.19.3.615] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
104 Nagoshi S. Osteopontin: Versatile modulator of liver diseases. Hepatol Res. 2014;44:22-30. [PMID: 23701387 DOI: 10.1111/hepr.12166] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
105 Xue YH, Zhang XF, Dong QZ, Sun J, Dai C, Zhou HJ, Ren N, Jia HL, Ye QH, Qin LX. Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma. Hepatology. 2010;52:2012-2022. [PMID: 20890897 DOI: 10.1002/hep.23942] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
106 Liao W, Huang G, Liao Y, Yang J, Chen Q, Xiao S, Jin J, He S, Wang C. High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma. Oncotarget 2014;5:10271-9. [PMID: 25431949 DOI: 10.18632/oncotarget.2082] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
107 Gong J, He XX, Tian A. Emerging role of microRNA in hepatocellular carcinoma (Review). Oncol Lett 2015;9:1027-33. [PMID: 25663852 DOI: 10.3892/ol.2014.2816] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
108 Sun BS, Li Y, Zhang ZF, You J, Wang CL. Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. Ann Thorac Surg 2013;96:1943-51. [PMID: 24094519 DOI: 10.1016/j.athoracsur.2013.07.089] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
109 Li Y, Sun BS, Pei B, Li CG, Zhang ZF, Yin YS, Wang CL. Osteopontin-expressing macrophages in non-small cell lung cancer predict survival. Ann Thorac Surg 2015;99:1140-8. [PMID: 25725928 DOI: 10.1016/j.athoracsur.2014.11.054] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
110 Lamour V, Le Mercier M, Lefranc F, Hagedorn M, Javerzat S, Bikfalvi A, Kiss R, Castronovo V, Bellahcène A. Selective osteopontin knockdown exerts anti-tumoral activity in a human glioblastoma model. Int J Cancer 2010;126:1797-805. [PMID: 19609945 DOI: 10.1002/ijc.24751] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
111 Desert R, Ge X, Song Z, Han H, Lantvit D, Chen W, Das S, Athavale D, Abraham-Enachescu I, Blajszczak C, Chen Y, Musso O, Guzman G, Hoshida Y, Nieto N. Role of Hepatocyte-Derived Osteopontin in Liver Carcinogenesis. Hepatol Commun 2021. [PMID: 34730871 DOI: 10.1002/hep4.1845] [Reference Citation Analysis]
112 Zheng Y, Zhou C, Yu XX, Wu C, Jia HL, Gao XM, Yang JM, Wang CQ, Luo Q, Zhu Y, Zhang Y, Wei JW, Sheng YY, Dong QZ, Qin LX. Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of β-Catenin. Cell Death Dis 2018;9:179. [PMID: 29415992 DOI: 10.1038/s41419-017-0226-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
113 Yoshida S, Furukawa N, Haruta S, Tanase Y, Kanayama S, Noguchi T, Sakata M, Yamada Y, Oi H, Kobayashi H. Theoretical model of treatment strategies for clear cell carcinoma of the ovary: focus on perspectives. Cancer Treat Rev 2009;35:608-15. [PMID: 19665848 DOI: 10.1016/j.ctrv.2009.07.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]